Cambridge, UK: Synoptics Health, a new division of Synoptics, a world leader in
the development and manufacture of innovative digital imaging systems for
scientific applications, today announced the world premier of its innovative
ProReveal Test, a rapid in-situ fluorescence-based method of detecting proteins
on surgical instruments in Hall 1, Stand F12 at Medica in Dusseldorf on 14th-17th November, 2012.
On stand, Synoptics Health experts will be showing the patented, ultra-sensitive
ProReveal Test, which combines an integrated ProReveal Protein Test Kit and a
ProReveal Viewer with easy-to-use touch screen and software. They will be
demonstrating how in just two simple spray and see steps, users can detect
nanogram levels of protein contamination, no matter where it is located on their
entire surgical instrument, in less than 5 minutes.
Synoptics Health staff will explain how this ProReveal Test has been developed
over four years in partnership with scientists at Queen Mary University of London
and is now available in the UK from Peskett Solutions and across the rest of the
world from Synoptics Health. Synoptics Health staff will also discuss how the
ProReveal Test aligns with the protein contamination testing recommendations in
the UK’s new NHS CFPP-01-01 consultation document.
Paul Ellwood, CEO of Synoptics Health explained: “We are delighted to be
introducing our revolutionary new test at the leading show for medical technology innovation. The ProReveal Test uses very sensitive, yet cost-effective
fluorescence technology and will tell you exactly where, and how much protein is
on your surgical instrument. This is a significant quality enhancement from current
testing available and there isn’t any other affordable fluorescence-based test
designed for this application that is commercially available, so it really is a first at
Ellwood continued: “We look forward to welcoming visitors to stand F12 at Medica and to discussing with them how they could integrate the ProReveal Test into their workflow to help them optimise their decontamination process and thus ensure they continue to supply clean, safe surgical instruments, which comply with current and future quality standards.”
For Further Information Contact:
Jayne Arthur, Synoptics Health, Beacon House, Nuffield Road, Cambridge, CB4 1TF, UK.
Tel: +44(0) 1223-727114 Fax +44 (0) 1223-727101
Email: email@example.com Web site: www.synopticshealth.com
Dr Sue Pearson, Director, International Science Writer, PO Box 170, Hitchin, Hertfordshire SG5 3GD, UK.
Tel/Fax +44 (0) 1462-635327 Email: firstname.lastname@example.org
Web: www.internationalsciencewriter.com Twitter:@isciencewriter
About Synoptics Health
Synoptics Health, based in Cambridge, UK is a new division of Synoptics, a world-leader in the development and manufacture of innovative digital imaging systems for a range of life science applications. The Company has three other divisions, Syngene, Syncroscopy and Synbiosis of which Syngene is the largest.
Syngene produces advanced systems for molecular biologists to analyse and document fluorescent DNA on gels and has systems in all the major pharmas and academic institutes world-wide. Synoptics’ other divisions Syncroscopy and Synbiosis specialise in digital imaging solutions for microscopy and microbial applications respectively. The Company founded in 1986, currently employs 45 people, 20 of whom are based at Synoptics Inc. in the USA.